Cargando…

Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes

To fully define clinical efficacy of highly active antiretroviral therapy for AIDS, analyze patients’ survival time and treatment mode after receiving treatment, and provide scientific theory to guide improvement of antiviral therapy, this paper selected 3100 cases of patients diagnosed with AIDS du...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Riying, Li, Guojian, Wu, Jizhou, Zhu, Yujia, Qin, Xionglin, Li, Shixiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881226/
https://www.ncbi.nlm.nih.gov/pubmed/27275121
http://dx.doi.org/10.1016/j.jsps.2016.04.004
_version_ 1782433937328439296
author Lv, Riying
Li, Guojian
Wu, Jizhou
Zhu, Yujia
Qin, Xionglin
Li, Shixiong
author_facet Lv, Riying
Li, Guojian
Wu, Jizhou
Zhu, Yujia
Qin, Xionglin
Li, Shixiong
author_sort Lv, Riying
collection PubMed
description To fully define clinical efficacy of highly active antiretroviral therapy for AIDS, analyze patients’ survival time and treatment mode after receiving treatment, and provide scientific theory to guide improvement of antiviral therapy, this paper selected 3100 cases of patients diagnosed with AIDS during April 2006 and April 2014 as object of this study. All patients were treated with highly active antiretroviral therapy. The main analysis contents of this study include CD4 + T lymphocyte count, viral load changes, incidence of opportunistic infections, specific cause of death and the like. The results show that patients’ CD4 + T lymphocyte levels are significantly increased 3, 18, and 24 months after treatment, difference between the situation after and before receiving treatment, P < 0.05, with statistically significant difference. Analyzed from effective inhibition of virus, effective inhibition rate is 72.58.0% (2250/3100). Main causes of death in patients is usually respiratory failure. It thus can be concluded that highly active antiretroviral therapy for AIDS is with good clinical effect, which can effectively improve survival time of patients. So it enjoys application value of being widely used in clinical treatment of AIDS.
format Online
Article
Text
id pubmed-4881226
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48812262016-06-06 Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes Lv, Riying Li, Guojian Wu, Jizhou Zhu, Yujia Qin, Xionglin Li, Shixiong Saudi Pharm J Original Article To fully define clinical efficacy of highly active antiretroviral therapy for AIDS, analyze patients’ survival time and treatment mode after receiving treatment, and provide scientific theory to guide improvement of antiviral therapy, this paper selected 3100 cases of patients diagnosed with AIDS during April 2006 and April 2014 as object of this study. All patients were treated with highly active antiretroviral therapy. The main analysis contents of this study include CD4 + T lymphocyte count, viral load changes, incidence of opportunistic infections, specific cause of death and the like. The results show that patients’ CD4 + T lymphocyte levels are significantly increased 3, 18, and 24 months after treatment, difference between the situation after and before receiving treatment, P < 0.05, with statistically significant difference. Analyzed from effective inhibition of virus, effective inhibition rate is 72.58.0% (2250/3100). Main causes of death in patients is usually respiratory failure. It thus can be concluded that highly active antiretroviral therapy for AIDS is with good clinical effect, which can effectively improve survival time of patients. So it enjoys application value of being widely used in clinical treatment of AIDS. Elsevier 2016-05 2016-04-26 /pmc/articles/PMC4881226/ /pubmed/27275121 http://dx.doi.org/10.1016/j.jsps.2016.04.004 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Lv, Riying
Li, Guojian
Wu, Jizhou
Zhu, Yujia
Qin, Xionglin
Li, Shixiong
Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
title Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
title_full Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
title_fullStr Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
title_full_unstemmed Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
title_short Research on AIDS patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
title_sort research on aids patients’ survival time after highly active antiretroviral therapy, treatment effect and treatment modes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881226/
https://www.ncbi.nlm.nih.gov/pubmed/27275121
http://dx.doi.org/10.1016/j.jsps.2016.04.004
work_keys_str_mv AT lvriying researchonaidspatientssurvivaltimeafterhighlyactiveantiretroviraltherapytreatmenteffectandtreatmentmodes
AT liguojian researchonaidspatientssurvivaltimeafterhighlyactiveantiretroviraltherapytreatmenteffectandtreatmentmodes
AT wujizhou researchonaidspatientssurvivaltimeafterhighlyactiveantiretroviraltherapytreatmenteffectandtreatmentmodes
AT zhuyujia researchonaidspatientssurvivaltimeafterhighlyactiveantiretroviraltherapytreatmenteffectandtreatmentmodes
AT qinxionglin researchonaidspatientssurvivaltimeafterhighlyactiveantiretroviraltherapytreatmenteffectandtreatmentmodes
AT lishixiong researchonaidspatientssurvivaltimeafterhighlyactiveantiretroviraltherapytreatmenteffectandtreatmentmodes